Skip to main content

Aligos Therapeutics, Inc. (ALGS)

NASDAQ: ALGS · IEX Real-Time Price · USD
15.82 -0.02 (-0.13%)
Sep 24, 2021 1:41 PM EDT - Market open
Market Cap673.65M
Revenue (ttm)2.46M
Net Income (ttm)-125.21M
Shares Out39.52M
EPS (ttm)-4.57
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume27,783
Open15.90
Previous Close15.84
Day's Range15.73 - 16.13
52-Week Range12.82 - 37.51
Betan/a
AnalystsBuy
Price Target34.75 (+119.7%)
Est. Earnings DateNov 4, 2021

About ALGS

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-ß...

IndustryBiotechnology
IPO DateOct 16, 2020
Employees86
Stock ExchangeNASDAQ
Ticker SymbolALGS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ALGS stock is "Buy." The 12-month stock price forecast is 34.75, which is an increase of 119.66% from the latest price.

Price Target
$34.75
(119.66% upside)
Analyst Consensus: Buy

News

Aligos Therapeutics to Present at the Cantor Virtual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u...

3 days ago - GlobeNewsWire

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results

Raised $83.6 million in gross proceeds from common stock offering STOPS™  and CAM programs: initial data presented at conferences, dosing in 2 nd CHB cohorts ongoing Clinical trial application filed for...

1 month ago - GlobeNewsWire

Aligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021

SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address un...

1 month ago - GlobeNewsWire

Aligos Therapeutics Raises $84M Via Equity At 7% Discount

Aligos Therapeutics Inc (NASDAQ: ALGS) has priced a previously announced underwritten public offering of 4.4 million shares at $19 per share, representing a discount of 7% from the last close price of $...

2 months ago - Benzinga

Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its underwritten public offering of 4,400,000 shares of common stoc...

2 months ago - GlobeNewsWire

Aligos Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has commenced an underwritten public offering of 4,000,000 shares of commo...

2 months ago - GlobeNewsWire

Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of...

-Five scientific posters to be presented at upcoming EASL ILC meeting - All 4 Aligos CHB development candidates continue to advance – STOPS™ molecule and CAM drug candidates are currently being evaluate...

3 months ago - GlobeNewsWire

Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at ...

Subjects experienced a 2.9 log 10 IU/mL mean reduction in HBV DNA levels after 14 days' dosing with 100 mg ALG-000184

3 months ago - GlobeNewsWire

Aligos Therapeutics to Present at the Jefferies Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unm...

4 months ago - GlobeNewsWire

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2021 Financial Results

Advancement of Aligos' drug candidates continues to be on track Advancement of Aligos' drug candidates continues to be on track

4 months ago - GlobeNewsWire

Aligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of Directors

SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u...

4 months ago - GlobeNewsWire

Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chron...

Aligos now evaluating two of its four Chronic Hepatitis B (CHB) portfolio drug candidates in patients Aligos now evaluating two of its four Chronic Hepatitis B (CHB) portfolio drug candidates in patients

5 months ago - GlobeNewsWire

Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

- Advanced ALG-010133 and ALG-000184 into the clinic - both expected to generate safety and antiviral activity data in Chronic Hepatitis B (CHB) patients in 2021 - Listed on NASDAQ Global Select Market ...

6 months ago - GlobeNewsWire

Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatit...

The first drug candidate in Aligos's chronic hepatitis B portfolio to be administered to CHB patients The first drug candidate in Aligos's chronic hepatitis B portfolio to be administered to CHB patients

6 months ago - GlobeNewsWire

Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on R...

SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u...

6 months ago - GlobeNewsWire

Aligos (ALGS) in Focus: Stock Moves 5.6% Higher

Aligos (ALGS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

Aligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Ol...

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has entered into an Exclusive License and Research Collaboration Agreement...

9 months ago - GlobeNewsWire

Aligos Therapeutics Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler...

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address un...

10 months ago - GlobeNewsWire

Aligos Therapeutics is awarded €1.8M VLAIO grant to advance chronic hepatitis B research

SOUTH SAN FRANCISCO, Calif. and LEUVEN, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therap...

10 months ago - GlobeNewsWire

Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184...

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address un...

10 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: Solar Technology Shines In A 9-IPO Week

Nine IPOs and five SPACs went public this past week, and one IPO postponed.

11 months ago - Seeking Alpha

Aligos Therapeutics stock rallies out of the gate, then pulls back

Shares of Aligos Therapeutics Inc. rallied out of the gate Friday, as they opened 16% above the initial public offering price. The stock's first trade on the Nasdaq was at $17.40 at 1:33 p.m.

11 months ago - Market Watch

Aligos Therapeutics Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its initial public offering of 10,000,000 shares of its common stoc...

11 months ago - GlobeNewsWire